This study is testing a new way to help surgeons see brain tumors better during surgery. It uses a special substance called panitumumab-IRDye800, which is given through an IV. This substance attaches to tumor cells and glows when a special camera (POINPOINT-IR9000) is used. This might help surgeons tell the difference between tumor cells and healthy brain tissue, and find small tumors that are hard to see otherwise. The main goal is to see if panitumumab-IRDye800 is safe and what dose works best. You could join if you are 18 or older, have a suspected or confirmed diagnosis of glioblastoma or vestibular schwannoma, and are planning to have surgery to remove your tumor. The study is currently unclear on its recruitment status and plans to enroll 46 participants.

Study design

This is a Phase 1/2 study that will test different doses of panitumumab-IRDye800. It will involve a total of 46 participants.

What's involved

You would receive panitumumab-IRDye800 through an IV and undergo near-infrared imaging during your tumor removal surgery.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored for up to 30 days after receiving the study treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.